Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Liquidia announces FDA acceptance of NDA resubmission for YUTREPIA
Liquidia (LQDA) announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for YUTREPIA inhalation ...
Novo Nordisk inks licensing pact with Lexicon for obesity candidate
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech ...
thederrick.com2d
Buscabulla teases summer US tour and new album, ‘Se Amaba Así’
Puerto Rican indie-pop act Buscabulla is entering a new era. Nearly five years after the release of its critically acclaimed debut album, “Regresa,” the duo has announced an upcoming U.S.